---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-023484"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:27:21.052619+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fennec announces TGH Cancer Institute study of PEDMARK for ototoxicity in AYA and adult patients

## Summary
- Tampa General Hospital Cancer Institute initiates real-world study of PEDMARK (sodium thiosulfate) to reduce ototoxicity risk in AYA and adult patients receiving cisplatin.
- Study aims to evaluate clinical utility and audiology monitoring to inform future research on hearing loss prevention.
- PEDMARK currently FDA-approved for pediatric patients 1 month+ with localized non-metastatic solid tumors; NCCN 2A recommendation for AYA.
- Gene A. Wetzstein, PharmD, BCOP, of TGH Cancer Institute is principal investigator; Fennec's CMO Pierre Sayad comments on real-world evidence.

## SEC filing metadata
- accession: 0001104659-26-023484
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465926023484/0001104659-26-023484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465926023484/fencf-20260304x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-023484
- JSON: https://secwatch.observer/filing/0001104659-26-023484.json
- Plain text: https://secwatch.observer/filing/0001104659-26-023484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.